Cineverse Corp. (Cinedigm Corp.) 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on October 19, 2022, reporting events occurring on October 17, 2022. The registrant, Cinedigm Corp. (trading symbol: CIDM), is incorporated in Delaware and listed on the Nasdaq Capital Market. The filing primarily addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
Material Changes and Executive Compensation
On October 17, 2022, the Company entered into a new employment agreement with Christopher J. McGurk, CEO and Chairman of the Board. Key terms include:
- Term: Effective April 1, 2023, through March 31, 2026, with an automatic one-year renewal option.
- Base Salary: $650,000 annually.
- Target Bonus: $650,000 under the Management Annual Incentive Plan, subject to goals set by the Compensation Committee.
- Equity Awards:
- Up to 500,000 Performance Share Units (PSUs) subject to EBITDA and financial performance targets.
- 2,500,000 Stock Appreciation Rights (SARs) with an exercise price of $0.48 and a 10-year term. Vesting occurs in three equal tranches on April 1 of 2023, 2024, and 2025.
- Change in Control Provisions: Unvested SARs immediately vest upon a Change in Control or termination other than for Cause.
Severance and Termination Provisions
The agreement outlines specific payouts for termination without Cause or resignation for Good Reason:
- Standard Termination: The greater of remaining term base salary or 18 months' base salary, plus 1.5 times the average of the last two bonus payments.
- Change in Control Termination: If termination occurs within two years of a Change in Control, the executive receives a lump sum equal to three times the sum of the current annual base salary and the target bonus for the year of termination.
Investor Verification Checklist
- Verify the exact vesting schedule and performance metrics for the 500,000 PSUs, as specific EBITDA targets are determined by the Compensation Committee.
- Confirm the current stock price relative to the $0.48 exercise price of the 2.5 million SARs to assess immediate dilution potential.
- Review the full text of Exhibit 10.1 for definitions of "Cause" and "Good Reason" which trigger severance payments.
- Monitor future filings for the actual grant date and valuation of the equity awards.